Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.53 |
| ▸ | MET | P08581 | 18/20 | 0.48 |
| ▸ | KDR | P35968 | 13/20 | 0.47 |
| ▸ | MST1R | Q04912 | 2/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563608 | 0.94 | AXL (0.54) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL3564006 | 0.93 | AXL (0.53) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL3562169 | 0.89 | AXL (0.51) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL3566795 | 0.88 | AXL (0.58) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL3562384 | 0.85 | MET (0.57) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL3560801 | 0.76 | MET (0.49) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL4330366 | 0.75 | MET (0.65) | AXLMETKDRMERTK | |
| SCHEMBL3613361 | 0.73 | MET (0.62) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL3555603 | 0.72 | MET (0.62) | AXLMETKDRMST1RNTRK1 | |
| SCHEMBL4328187 | 0.71 | AXL (0.57) | AXLMETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2125781-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214544-A1 | Substituted heterocycles and methods of use | HGF, MET, HGFAC | AXL 202/4885MET 2/4885KDR 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.